{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:10:19Z","timestamp":1773479419480,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The number of non-inferiority (NI) trials, those aiming to show a new treatment is no worse than a comparator, is increasing. However, their added complexity over superiority trials can create confusion. Most guidance and reviews to date have an industry focus with research suggesting these trials may differ from publicly funded NI trials. The aim of this work is to review the design and reporting characteristics of UK publicly funded NI trials. This assessment will show how well recommendations from industry are translating to publicly funded trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The International Standard Randomised Controlled Trial Number web registry and the National Institute for Health and Care Research\u2019s Funding and Awards Library and Journals Library were searched using the term non-inferiority and logical synonyms. Inclusion requirements were a UK publicly funded NI randomised controlled trial. Characteristics of the design, analyses and results as available were recorded on a dedicated data extraction spreadsheet. Appropriate summary statistics were used to present the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Searches completed on the 14th of January 2022 identified 477 potential trials which after exclusions resulted in a database of 114 NI trials to be summarised. Non-inferiority margins were defined for most trials with a median of 8% (IQR: 3\u201310%) used for risk differences (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200958) and 0.35 (IQR: 0.26\u20130.43) standardised mean difference for continuous outcomes (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930). Justifications for the margin chosen (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200962) were more commonly based on the clinical importance (49\/62) and less commonly using statistical considerations (13\/62). The most prevalent primary analysis population was solely on an intention-to-treat basis (49\/114). The superiority of the treatment was well described but not always included as an outcome and only powered for in about a third of cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aspects of NI trial design are well described but not always in line with current recommendations. Of particular note, is the absence of statistical considerations when setting the non-inferiority margin, which eliminates the ability to confirm indirect superiority over placebo for the new treatment. Additionally, despite suggestions that it can increase the type 1 error in NI trials, the use of the intention-to-treat alone is the most common analysis population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Research on Research ID: 3171\u00a0(registration date: 31st May 2023).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-024-08651-3","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T19:36:15Z","timestamp":1733254575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A review of UK publicly funded non-inferiority trials: is the design more inferior than it should be?"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1900-2773","authenticated-orcid":false,"given":"Nikki","family":"Totton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Julious","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Walters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Coates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"106","key":"8651_CR1","first-page":"1","volume":"12","author":"J Schumi","year":"2011","unstructured":"Schumi J, Wittes TJ. Through the looking glass: understanding non-inferiority. Trials. 2011;12(106):1\u201312.","journal-title":"Trials"},{"key":"8651_CR2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/sim.2584","volume":"25","author":"European Medicines Agency","year":"2006","unstructured":"European Medicines Agency. Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med. 2006;25:1628\u201338.","journal-title":"Stat Med"},{"key":"8651_CR3","doi-asserted-by":"crossref","unstructured":"Greene CJ, Morland LA, Durkalski VL, Frueh BC. Noninferiority and equivalence designs: Issues and implications for mental health research.\u00a0\u00a0J Trauma Stress. 2008;21(5):433\u20139.","DOI":"10.1002\/jts.20367"},{"key":"8651_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/CIRCULATIONAHA.119.040214","volume":"140","author":"B Bikdeli","year":"2019","unstructured":"Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, et al. Non-Inferiority Designed Cardiovascular Trials in Highest-Impact Journals: Main Findings, Methodological Quality and Time Trends. Circulation. 2019;140:379\u201389.","journal-title":"Circulation"},{"key":"8651_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: Design concepts and issues - The encounters of academic consultants in statistics. Stat Med. 2003;22:169\u201386.","journal-title":"Stat Med"},{"key":"8651_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.1315","volume":"22","author":"HMJ Hung","year":"2003","unstructured":"Hung HMJ, Wang SJ, Tsong Y, Lawrence J, O\u2019Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med. 2003;22:213\u201325.","journal-title":"Stat Med"},{"issue":"14","key":"8651_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1056\/NEJMra1510063","volume":"377","author":"L Mauri","year":"2017","unstructured":"Mauri L, D\u2019Agostino RBS. Challenges in the Design and Interpretation of Noninferiority Trials. N Engl J Med. 2017;377(14):1357\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"8651_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/pst.6","volume":"1","author":"S Julious","year":"2002","unstructured":"Julious S, Zariffa N. The ABC of pharmaceutical trial design: some basic principles. Pharm Stat. 2002;1(1):45\u201353.","journal-title":"Pharm Stat"},{"issue":"8","key":"8651_CR9","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/bcp.13280","volume":"83","author":"TA Althunian","year":"2017","unstructured":"Althunian TA, de Boer A, Groenwold RHH, Klungel OH. Defining the noninferiority margin and analysing noninferiority: An overview. Br J Clin Pharmacol. 2017;83(8):1636\u201342.","journal-title":"Br J Clin Pharmacol"},{"key":"8651_CR10","unstructured":"European Medicines Agency. ICH Topic E9: Statistical Principles for Clinical Trials. 1998. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf. Cited 2022 Mar 20."},{"key":"8651_CR11","unstructured":"European Medicines Agency. ICH Topic E10: Choice of Control Group in Clinical Trials. 2001. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-10-choice-control-group-clinical-trials-step-5_en.pdf. Cited 2022 Mar 20."},{"issue":"24","key":"8651_CR12","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. ONSORT Group for the Reporting of Noninferiority and Equivalence Randomized Trials. JAMA. 2012;308(24):2594.","journal-title":"JAMA"},{"key":"8651_CR13","unstructured":"Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry. 2016. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM202140.pdf. Cited 2022 Mar 15."},{"issue":"1","key":"8651_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1186\/s13063-022-06911-8","volume":"23","author":"N Attard","year":"2022","unstructured":"Attard N, Totton N, Gillies K, Goulao B. How do we know a treatment is good enough? A survey of non-inferiority trials. Trials. 2022;23(1):1021.","journal-title":"Trials"},{"key":"8651_CR15","doi-asserted-by":"publisher","first-page":"e012594","DOI":"10.1136\/bmjopen-2016-012594","volume":"6","author":"S Rehal","year":"2016","unstructured":"Rehal S, Morris TP, Fielding K, Carpenter JR, Phillips PPJ. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open. 2016;6:e012594.","journal-title":"BMJ Open"},{"issue":"107","key":"8651_CR16","first-page":"1","volume":"18","author":"T Althunian","year":"2017","unstructured":"Althunian T, de Boer A, Klungel O, Insani W, Groenwold R. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials. 2017;18(107):1\u20139.","journal-title":"Trials"},{"issue":"7","key":"8651_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3109\/0284186X.2012.702924","volume":"51","author":"ED Saad","year":"2012","unstructured":"Saad ED, Buyse M. Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects. Acta Oncol (Madr). 2012;51(7):890\u20136.","journal-title":"Acta Oncol (Madr)"},{"key":"8651_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/jcpt.12268","volume":"40","author":"M Gosho","year":"2015","unstructured":"Gosho M. Non-inferiority margins employed in clinical trials in Japan. J Clin Pharm Ther. 2015;40:289\u201398.","journal-title":"J Clin Pharm Ther"},{"key":"8651_CR19","unstructured":"Duro E. Non-inferiority Margin Setting from Indirect Comparison. University of Sheffield; 2019. Available from: https:\/\/etheses.whiterose.ac.uk\/28122\/. Cited 2023 Sept 22."},{"issue":"7","key":"8651_CR20","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-11-1653","volume":"18","author":"S Tanaka","year":"2012","unstructured":"Tanaka S, Kinjo Y, Kataoka Y, Yoshimura K, Teramukai S. Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review. Clin Cancer Res. 2012;18(7):1837\u201347.","journal-title":"Clin Cancer Res"},{"issue":"214","key":"8651_CR21","first-page":"1","volume":"13","author":"P Schiller","year":"2012","unstructured":"Schiller P, Burchardi N, Niestroj M, Kieser M. Quality of reporting of clinical non-inferiority and equivalence randomised trials - update and extension. Trials. 2012;13(214):1\u201312.","journal-title":"Trials"},{"issue":"10","key":"8651_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013550","volume":"5","author":"G Wangge","year":"2010","unstructured":"Wangge G, Klungel OH, Roes KCB, de Boer A, Hoes AW, Knol MJ. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS ONE. 2010;5(10): e13550.","journal-title":"PLoS ONE"},{"issue":"10","key":"8651_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jama.295.10.1147","volume":"295","author":"A Le Henanff","year":"2006","unstructured":"Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. J Am Med Assoc. 2006;295(10):1147\u201351.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"8651_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/bimj.200410085","volume":"47","author":"S Lange","year":"2005","unstructured":"Lange S, Freitag G. Choice of delta: requirements and reality - results of a systematic review. Biometrical J. 2005;47(1):12\u201327.","journal-title":"Biometrical J"},{"issue":"25","key":"8651_CR25","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1016\/j.jacc.2015.10.051","volume":"66","author":"SJ Pocock","year":"2015","unstructured":"Pocock SJ, Clayton TC, Stone GW. Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015;66(25):2886\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"8651_CR26","doi-asserted-by":"publisher","first-page":"e1696","DOI":"10.1093\/cid\/ciaa1353","volume":"73","author":"AD Bai","year":"2020","unstructured":"Bai AD, Komorowski AS, Lo CKL, Tandon P, Li XX, Mokashi V, et al. Methodological and Reporting Quality of Noninferiority Randomized Controlled Trials Comparing Antibiotic Therapies: A Systematic Review. Clin Infect Dis. 2020;73(7):e1696\u2013705.","journal-title":"Clin Infect Dis"},{"key":"8651_CR27","unstructured":"BMC. ISRCTN Registry. 2021. Available from: https:\/\/www.isrctn.com\/. Cited 2021 Aug 8."},{"key":"8651_CR28","unstructured":"National Institute for Health and Care Research. NIHR Local. 2021. Available from: https:\/\/local.nihr.ac.uk\/. Cited 2023 Sept 22."},{"key":"8651_CR29","unstructured":"National Institute for Health and Care Research. Funding and Awards Library. 2022. Available from: https:\/\/fundingawards.nihr.ac.uk\/. Cited 2022 Jan 26."},{"key":"8651_CR30","unstructured":"National Institute for Health and Care Research, National Institute for Health Research. Journals Library. 2022. Available from: https:\/\/www.journalslibrary.nihr.ac.uk\/#\/. Cited 2022 Jan 26."},{"issue":"10","key":"8651_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2017-015997","volume":"7","author":"MB Hakoum","year":"2017","unstructured":"Hakoum MB, Jouni N, Abou-Jaoude EA, Hasbani DJ, Abou-Jaoude EA, Lopes LC, et al. Characteristics of funding of clinical trials: Cross-sectional survey and proposed guidance. BMJ Open. 2017;7(10):1\u20139.","journal-title":"BMJ Open"},{"key":"8651_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12874-020-01143-3","volume":"20","author":"RB B\u00fcchter","year":"2020","unstructured":"B\u00fcchter RB, Weise A, Pieper D. Development, testing and use of data extraction forms in systematic reviews: a review of methodological guidance. BMC Med Res Methodol. 2020;20:259.","journal-title":"BMC Med Res Methodol"},{"key":"8651_CR33","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, PRISMA The, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"issue":"24","key":"8651_CR34","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","volume":"295","author":"G Piaggio","year":"2006","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJWW, Altman DG. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA - J Am Med Assoc. 2006;295(24):1152\u201360.","journal-title":"JAMA - J Am Med Assoc"},{"key":"8651_CR35","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Routledge Academic; 1988."},{"issue":"1","key":"8651_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-018-2886-y","volume":"19","author":"JC Rothwell","year":"2018","unstructured":"Rothwell JC, Julious SA, Cooper CL. A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal. Trials. 2018;19(1):1\u201313.","journal-title":"Trials"},{"key":"8651_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jclinepi.2023.06.022","volume":"161","author":"S Ofori","year":"2023","unstructured":"Ofori S, Cafaro T, Devereaux PJ, Marcucci M, Mbuagbaw L, Thabane L, et al. Noninferiority margins exceed superiority effect estimates for mortality in cardiovascular trials in high-impact journals. J Clin Epidemiol. 2023;161:20\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"8651_CR38","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/humrep\/dew256","volume":"31","author":"R Gupta","year":"2016","unstructured":"Gupta R, Gupta H, Banker M. The impact of an inappropriate non-inferiority margin in a non-inferiority trial. Hum Reprod. 2016;31(12):2892\u20133.","journal-title":"Hum Reprod"},{"issue":"1","key":"8651_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/pst.1716","volume":"15","author":"L Flight","year":"2016","unstructured":"Flight L, Julious SA. Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharm Stat. 2016;15(1):80\u20139.","journal-title":"Pharm Stat"},{"key":"8651_CR40","unstructured":"National Institute for Health and Care Research. A brief guide to patient and public involvement and qualitative methods within health and social care research. 2021. Available from: https:\/\/www.rds-nw.nihr.ac.uk\/wp-content\/uploads\/2021\/11\/RDS_Guide_to_PPI_qualitative_methods.pdf. Cited 2023 Jan 4."},{"key":"8651_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jclinepi.2018.07.004","volume":"104","author":"T Althunian","year":"2018","unstructured":"Althunian T, de Boer A, Groenwold R, Klungel O. Using a single non-inferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. J Clin Epidemiol. 2018;104:15\u201323.","journal-title":"J Clin Epidemiol"},{"key":"8651_CR42","unstructured":"The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products. Points To Consider on Switching Between Superiority and Non-Inferiority. 2000;(July). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-switching-between-superiority-non-inferiority_en.pdf. Cited 2023 Sept 22."},{"issue":"14","key":"8651_CR43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","volume":"377","author":"MA Hernan","year":"2017","unstructured":"Hernan MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. N Engl J Med. 2017;377(14):1391\u20138.","journal-title":"N Engl J Med"},{"key":"8651_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12874-021-01260-7","volume":"21","author":"AD Bai","year":"2021","unstructured":"Bai AD, Komorowski AS, Lo CKL, Tandon P, Li XX, Mokashi V, Cvetkovic A, Findlater A, Liang L, Tomlinson G, Loeb M, Mertz D. Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review. BMC Medical Research Methodology. 2021;21:75.","journal-title":"BMC Medical Research Methodology"},{"issue":"12","key":"8651_CR45","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/sim.10067","volume":"43","author":"M Dodd","year":"2024","unstructured":"Dodd M, Carpenter J, Thompson JA, Williamson E, Fielding K, Elbourne D. Assessing efficacy in non-inferiority trials with non-adherence to interventions: Are intention-to-treat and per-protocol analyses fit for purpose? Stat Med. 2024;43(12):2314\u201331.","journal-title":"Stat Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T20:02:25Z","timestamp":1733256145000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8651"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08651-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3384476\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the data are publicly available and do not directly involve human participants, hence this study did not require ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"809"}}